| 764548 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
641 Spatially organized multicellular immune hubs in MMRd and MMRp colorectal cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.641 |
Chen Jonathan, Pelka Karin, Hofree Matan, Giannakis Marios, Boland Genevieve, Aguirre Andrew, Anderson Ana, Rozenblatt-Rosen Orit, Regev Aviv, Hacohen Nir |
| 764547 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
456 A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIB/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress |
2021-11-01 |
10.1136/jitc-2021-sitc2021.456 |
Boyer Michael, Patel Sandip, Marron Thomas, Pavlakis Nick, Parakh Sagun, Gadgeel Shirish, Shafique Michael, Hoyer Robert, Ross Camidge D, Farber Charles, Mehra Ranee, Mekhail Tarek, Blinman Prunella, Kowalski Karey, Davis Craig, Pavlov Dmitri, Gad Nayra, Massarelli Erminia |
| 764546 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
455 Pegasus Lung, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL-2) with anti-cancer agents in patients with non-small cell lung cancer (NSCLC) and mesothelioma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.455 |
Meng Robin, Besse Benjamin, Johnson Melissa, Bennouna Jaafar, Toschi Luca, Abbadessa Giovanni, Amrate Amele, Zang Miao, Ares Luis Paz |
| 764545 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
454 Analysis of NY-ESO-1 expression in specimens from a Phase I/II NY-ESO-1 T-cell therapy clinical trial in non-small cell lung cancer and from exploratory studies in multiple tumor types |
2021-11-01 |
10.1136/jitc-2021-sitc2021.454 |
Barnes Bryan, Shan Ming, Blouch Kristin, Altan Mehmet, Kim Jaegil, Ramos-Hernandez Natalia, Corigliano Ellie |
| 764544 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
666 Deletion of Drp1 in T cells increases OXPHOS and CD8+ memory T cell population |
2021-11-01 |
10.1136/jitc-2021-sitc2021.666 |
Bullock Timothy, Gonzales Marissa |
| 764543 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
453 Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.453 |
Yarchoan Mark, Gane Edward, Marron Thomas, Rochestie Sarah, Cooch Neil, Peters Joann, Csiki Ildiko, Perales-Puchalt Alfredo, Sardesai Niranjan |
| 764542 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
452 Preliminary analysis of a real-world study (RWS) of camrelizumab treatment in primary liver cancer (PLC) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.452 |
Chen Zhendong, Wang Nianfei, Luo Dayong, Jiang Bo, Yuan Mu, Li Xinzhong, Yao Chunmei, Qian Hong, Kan Qingsheng, Wang Erxuan |
| 764541 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
450 Trial in progress: A phase 1b study of alrizomadlin, alone or plus 5-azacitidine or cytarabine, in pts with relapsed/refractory acute myeloid leukemia and relapsed higher-risk myelodysplastic syndrome |
2021-11-01 |
10.1136/jitc-2021-sitc2021.450 |
Zhai Yifan, Wang Jianxiang |
| 764540 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
445 Trial in progress: A phase 1b/2 study of alrizomadlin (APG-115), alone or combined with 5-azacitidine, in patients with relapsed/refractory acute myeloid leukemia (R/R AML) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.445 |
Zhai Yifan, Kadia Tapan |
| 764539 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
439 A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03 |
2021-11-01 |
10.1136/jitc-2021-sitc2021.439 |
Park Jong Chul, Harrington Kevin, Keam Bhumsuk, Machiels Jean-Pascal, Oosting Sjoukje, Welliver Tim, Guan Shanhong, Jin Feng, Forgie Alison, Fanning Philip, Ruffner Katherine, Pons Jaume, Randolph Sophia, Cohen Ezra |
